Page 465 - Binder2

• A patient with hemophilia takes a shelf-stable
therapy that works in both Earth orbit and rural
clinics.
• Regulatory submissions include not just ADA
rates—but tolerance curves, mucosal biomarkers,
and patient-reported immune fatigue.
• Biotech companies are valued not by how fast they
get to market—but how long their therapies last in
real patients.

This is not science fiction. It’s already happening—in pilot
trials, early platforms, and next-generation delivery
systems. We just haven’t made it the default yet.

The Core Principle: Health is a Human Right

At its core, this new contract is not just about immune
response. It’s about expectations. It’s about justice. It’s
about recognizing that people deserve therapies that
last—not because they’re lucky or rich or genetically
compatible, but because that is what medicine should be.

And if we do this right—if we build this new ecosystem—
we don’t just solve the tolerization crisis.

We establish a new standard for what biologics should be.

8.5 – Global Equity and the Tolerization Divide

Tolerization is not just a scientific problem. It’s a
distributional one.

463